Colorectal Cancer Molecular Diagnostics Market Report 2026

Colorectal Cancer Molecular Diagnostics Market Overview

• Colorectal Cancer Molecular Diagnostics market size has reached to $2.78 billion in 2025 • Expected to grow to $4.15 billion in 2030 at a compound annual growth rate (CAGR) of 8.3% • Growth Driver: The Impact Of Increasing Colorectal Cancer Prevalence On The Colorectal Cancer Molecular Diagnostics Market • Market Trend: Advancements in Non-Invasive Early Detection for Colorectal Cancer • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

The key promising market opportunities in the colorectal cancer molecular diagnostics market include: • Reagents and Kits (Segmentation By Type) → Expected gain of $858.02 Million • Hospitals (Segmentation By End Users) → Expected gain of $731.44 Million • Polymerase Chain Reaction (PCR) (Segmentation By Technology) → Expected gain of $676.91 Million

What Is Covered Under Colorectal Cancer Molecular Diagnostics Market?

Colorectal cancer, also known as colon cancer or rectal cancer, is a malignant tumor that develops in the colon (the large intestine) or the rectum (the final portion of the digestive tract just before the anus). It is a type of cancer that arises from the inner lining of these parts of the gastrointestinal system. Colorectal cancer molecular diagnostics uses advanced techniques to identify specific genetic mutations, alterations, and biomarkers that play a role in the development, progression, and treatment response of colorectal cancer. The main types of colorectal cancer molecular diagnostics are instruments, reagents, kits, and services. An instrument refers to a specialized tool or device designed to analyze and detect molecular changes, such as genetic mutations, variations in gene expression, or specific biomolecules, within biological samples of colorectal cancer patients. The molecular diagnostic solutions are also based on technologies such as polymerase chain reaction (PCR), sequencing, mass spectrometry, transcription-mediated amplification, chips and microarrays, and isothermal nucleic acid amplification technology (INAAT) used by end users such as hospitals, ambulatory surgical centers, diagnostic laboratories, and homecare settings.

What Is The Colorectal Cancer Molecular Diagnostics Market Growth Forecast?

The colorectal cancer molecular diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.15 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing investments in precision oncology, rising demand for minimally invasive diagnostics, expansion of genomic testing programs, growing integration of ai in cancer diagnostics, increasing focus on treatment response monitoring. Major trends in the forecast period include increasing adoption of molecular biomarker testing, rising use of pcr and sequencing technologies, growing demand for personalized oncology diagnostics, expansion of companion diagnostic development, enhanced focus on early cancer detection.

What Is The Driver Of The Colorectal Cancer Molecular Diagnostics Market?

The rising prevalence of colorectal cancer is expected to propel the growth of the colorectal cancer molecular diagnostics market going forward. Colorectal cancer is a disease that affects the colon or rectum, which are parts of the digestive system. Colorectal cancer occurs when cells in the colon or rectum grow out of control and form a tumor. The increase in colorectal cancer increases the demand for molecular diagnostics for cancer detection and treatment. For instance, in March 2023, according to the American Cancer Society, a US-based nationwide voluntary health organization dedicated to eliminating cancer, roughly 153,020 people are expected to receive a diagnosis of CRC (colorectal cancer), and out of that number, approximately 52,550 individuals are projected to succumb to the disease. Among those affected, there will be 19,550 cases and 3,750 deaths occurring in individuals under the age of 50. Therefore, the rising prevalence of colorectal cancer is driving the growth of the colorectal cancer molecular diagnostics industry.

How Will The Drivers Impact Growth In The Global Colorectal Cancer Molecular Diagnostics Market?

• Growing Aging Population (High) – The growing aging population will become a key driver of growth in the colorectal cancer molecular diagnostics market by 2030 As the global population continues to live longer, the proportion of older adults is steadily increasing and age is recognized as one of the major risk factors for colorectal cancer. This demographic trend is expected to create a stronger need for reliable diagnostic solutions that can enable early detection, continuous monitoring and effective disease management in older individuals. Moreover, elderly populations are more likely to participate in screening programs and require advanced diagnostic approaches to guide treatment decisions, thereby fueling the adoption of molecular diagnostic technologies. The share of older people is rising worldwide, with aging populations contributing significantly to the overall disease burden, including colorectal cancer. As a result, the growing aging population is anticipated to contributing to a 2.0%. annual growth in the market. • Increasing Healthcare Expenditure (Medium) – The increasing healthcare expenditure will emerge as a major factor driving the expansion of the market by 2030. As overall health spending continues to rise, more funds are becoming available for advanced diagnostic technologies, broader screening programs and precision medicine approaches. Greater investment in healthcare systems enables adoption of cutting-edge molecular assays, improved lab infrastructure and more widespread access to diagnostics. Consequently, the increasing healthcare expenditure is projected to contributing to a 1.5% annual growth in the market. • Growing Investments And Funding In Cancer Diagnostics Startups (Medium) – The growing investments and funding in cancer diagnostics startups will serve as a key growth catalyst for the market by 2030, Venture capital and private equity flows are increasingly targeted toward companies innovating in diagnostics, particularly those working on early detection, biomarker assays and precision genomic technologies. Such investments enable rapid development of new tests, improved commercialization and broader deployment of molecular diagnostics tools. Moreover, funding boosts support for infrastructure, regulatory approvals and scaling up manufacturing, which are essential for making advanced diagnostics accessible and affordable. Cancer-focused startups have raised nearly millions over the past year, with a significant share going to diagnostics players using AI, genomics and non-invasive detection technologies. Therefore, this growing investments and funding in cancer diagnostics startups is projected to supporting to a 1.0% annual growth in the market. • Rising Demand For Non-Invasive And Home-Based Testing (Low) – The rising demand for non-invasive and home-based testing will become a significant driver contributing to the growth of the market by 2030 Patients increasingly prefer diagnostic options that are convenient, private and less invasive, leading to a surge in the adoption of at-home screening tests. These tests, such as fecal immunochemical tests (FIT) and stool DNA assays, allow individuals to collect samples in the comfort of their homes and send them to laboratories for analysis, eliminating the need for clinic visits and complex bowel preparations. This shift not only enhances patient compliance but also expands access to early detection, particularly among populations hesitant to undergo traditional colonoscopies. Consequently, the rising demand for non-invasive and home-based testing is projected to contributing to a 0.6% annual growth in the market.

How Will The Restraints Impact Growth In The Global Colorectal Cancer Molecular Diagnostics Market?

• Stringent And Evolving Regulatory Frameworks (High) – Stringent And Evolving Regulatory Frameworks will restrict the growth of the Colorectal Cancer Molecular Diagnostics market during the forecast period. Molecular diagnostic tests for colorectal cancer must comply with evolving regulatory requirements from agencies like the FDA and EMA. These regulations ensure test accuracy and clinical validity but add significant time and cost to product development and approval. The growing emphasis on lab-developed test (LDT) regulation further complicates the market landscape, impacting product commercialization. • Lack Of Standardized Protocols Across Laboratories (Medium) – Lack Of Standardized Protocols Across Laboratories will restrict the growth of the Colorectal Cancer Molecular Diagnostics market during the forecast period. The absence of universal standardized protocols for molecular diagnostic testing creates variability in test results across different laboratories and healthcare settings. This inconsistency affects diagnosis accuracy, treatment decisions, and comparative effectiveness research. Lack of interoperability between platforms and data formats further complicates large-scale implementation and clinical adoption. • Impact Of Trade War And Tariff (Medium) – Impact Of Trade War And Tariff will restrict the growth of the Colorectal Cancer Molecular Diagnostics market during the forecast period. Trade disputes impact the cost and availability of diagnostic reagents, instrumentation, and specialized consumables essential for molecular testing. Tariffs on imported laboratory equipment and materials increase operational costs for diagnostic laboratories, potentially limiting testing availability and increasing costs for patients.

Key Players In The Global Colorectal Cancer Molecular Diagnostics Market

Major companies operating in the colorectal cancer molecular diagnostics market are Johnson & Johnson, Bayer AG, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Biocartis Group NV, Agilent Technologies Inc., Grifols S.A, Hologic Inc., Biomérieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Illumina Inc., Cepheid, Myriad Genetics Inc., Guardant Health, Luminex Corporation, GenMark Diagnostics, Amoy Diagnostics Co. Ltd., MDxHealth Inc., HTG Molecular Diagnostics Inc., GenPath Diagnostics, geneOmbio Technologies Pvt.

Global Colorectal Cancer Molecular Diagnostics Market Trends and Insights

Major companies operating in the colorectal cancer molecular diagnostics market are focusing on developing innovative solutions, such as blood-based liquid biopsy screening tests, to meet the rising demand for non-invasive, early detection tools, improved patient compliance versus colonoscopy, and broader population screening as guidelines and reimbursement evolve. A liquid biopsy is a blood test that detects tumour-derived biomarkers from a simple blood draw; its key features include minimal invasiveness, the ability to screen asymptomatic populations, and molecular-level sensitivity that complements. For instance, in July 2024, Guardant Health, a United States-based precision oncology company, launched Shield, a blood-based colorectal cancer screening test that was approved by the U.S. Food and Drug Administration as a primary screening option for average-risk adults 45 and older. Shield is a multi-marker blood assay that analyses circulating tumour signals to identify people likely to have colorectal cancer; it was developed and validated in the large ECLIPSE clinical programme and demonstrated high sensitivity and specificity sufficient for FDA primary-screening designation. The test’s composition and functionality combine sequencing and proprietary bioinformatic classifiers to detect methylation and other tumour-derived signals in plasma. Its unique features include convenience (single blood draw), potential to increase screening uptake, and a pathway to Medicare coverage, and its applications are population screening and triage to diagnostic colonoscopy for positives, offering earlier detection with fewer invasive procedures.

What Are Latest Mergers And Acquisitions In The Colorectal Cancer Molecular Diagnostics Market?

In July 2023, New Day Diagnostics LLC, a US-based medical equipment manufacturing company, acquired the assets of Epigenomics AG for an undisclosed amount. With this acquisition, New Day Diagnostics broadens its offerings within cancer diagnostics, overtaking intellectual property belonging to Epigenomics AG, including Epi ProColon, a screening technology aimed at the non-invasive identification of colorectal cancer. Epigenomics AG is a Germany-based colorectal cancer molecular diagnostics company.

What Defines the Colorectal Cancer Molecular Diagnostics Market?

The colorectal cancer molecular diagnostics market consists of revenues earned by entities by providing diagnostic genetic mutation analysis, biomarker profiling, and epigenetic analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The colorectal cancer molecular diagnostics market consists of sales of molecular diagnostic biochips, liquid biopsy kits, and bioinformatics software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Colorectal Cancer Molecular Diagnostics Market Report 2026?

The colorectal cancer molecular diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer molecular diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.